The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

19 May 2010 15:32

RNS Number : 2180M
Cathay International Holdings Ld
19 May 2010
 



 

19 May 2010

 

Cathay International Holdings Limited

Interim Management Statement

 

Cathay International Holdings Limited (the "Company") announces its Interim Management Statement for the period from 1 January 2010 to 14 May 2010:

 

Highlights of the period

 

·; On 21 January 2010, the Company announced, inter alia, the appointment of Mr. Lee Jin Yi as an executive director and Chief Executive Officer of the Company and the appointment of Mr Eric Siu as Finance Director of the Company.

 

·; On 12 February 2010, the Company announced further investments in Xian Haotian Bio-Engineering Technology Co. Limited ("Xian Haotian") and its subsidiaries and related companies (the "Xian Haotian Group").

 

·; On 1 April 2010, the Company announced the flotation of Lansen Pharmaceutical Holdings Company Limited ("Lansen"), a subsidiary of the Company, on the Hong Kong Stock Exchange, and the associated partial disposal of Lansen.

 

·; On 27 April 2010, the Company announced the preliminary annual results of the Group for the year ended 31 December 2009.

 

·; On 6 May 2010, the Company announced the successful closing of the placing and public offer of shares in Lansen.

 

Further investments in the Xian Haotian Group

 

On 12 February 2010, the Company announced further investments in the Xian Haotian Group, following which Xian Haotian is now an indirectly wholly owned subsidiary of the Company. The investment made in the Xian Haotian Group during the period was approximately US$13 million, which brings the total investment made to date to approximately US$33 million.

The Xian Haotian Group is one of the Company's major investments in the healthcare and pharmaceutical sector in China. Going forward, inositol will be the core product of the Xian Haotian Group, and the Company anticipates that the inositol business will become a major contributor to the growth in the Group's profits in 2011 and beyond. The inositol project is expected to commence production in the second half of 2010.

 

Flotation and Partial Disposal of Lansen

 

As announced on 6 May 2010, the public offer of shares in Lansen was approximately 852 times oversubscribed and the flotation offer price was set at HK$3.91 per share. The net proceeds of the flotation payable to Lansen, after deducting fees and expenses, were approximately HK$350.4 million (US$45.1 million). The net proceeds of the partial disposal received by the Company were approximately HK$114.9 million (US$14.8 million). Dealings in Lansen's shares on the Hong Kong Stock Exchange commenced on 7 May 2010.

 

Following completion of the flotation and the partial disposal, the Company indirectly holds approximately 52.46% of Lansen. Assuming that the over-allocation option provided under the terms of the flotation is exercised in full, the Company will indirectly hold approximately 50.56% of Lansen.

 

The effect of the flotation and partial disposal on the financial position of the Group has been an increase in net assets.

 

The financial performance of the Group in the period since the 2009 year end have been in line with the Company's expectations, and the outlook for the full year remains unchanged that expressed in our preliminary announcement of results on 27 April 2010.

 

Except for the further investment in the Xian Haotian Group and the net proceeds received from the flotation and partial disposal of Lansen, there has been no significant change to the financial position of the Group since that reported as at 31 December 2009.

 

 

For further information, please contact:

 

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

(via Brunswick)

020 7404 5959

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZKLFFBEFLBBK
Date   Source Headline
30th Aug 201911:33 amRNSInterim Results
27th Aug 20194:10 pmRNSLansen reports interim results ended 30 June 2019
16th Aug 201911:46 amRNSNotice of Interim Results
1st Aug 20199:52 amRNSBlock listing Interim Review
25th Jul 201911:34 amRNSTrading Update
12th Jul 20199:24 amRNSChange of Registered Office Address in Bermuda
8th Jul 201912:32 pmRNSUpdate on cross guarantee agreement
28th Jun 20197:00 amRNSTotal Voting Rights
21st Jun 201911:56 amRNSUpdate re Natural Dailyhealth
21st Jun 201910:58 amRNSStatement relating to UK FCA enforcement action
20th Jun 201912:01 pmRNSUpdate on renewal of Cross Guarantee Agreement
12th Jun 201912:02 pmRNSChange of Company Secretary
12th Jun 201911:59 amRNSUpdate on renewal of Cross Guarantee Agreement
11th Jun 201911:41 amRNSDisposal of Starry Shares
10th Jun 20194:08 pmRNSResult of AGM
31st May 201910:51 amRNSStatement relating to UK FCA enforcement action
14th May 201911:54 amRNSDisposal of Starry Shares
3rd May 20192:24 pmRNSRenewal of Cross Guarantee
24th Apr 201912:23 pmRNSStarry Share Disposal
12th Apr 20199:42 amRNSResult of Special General Meeting
29th Mar 201912:49 pmRNSAnnual Results For the Year Ended 31 December 2018
27th Mar 20194:59 pmRNSProposed Further Disposal of Starry Shares
27th Mar 20198:01 amRNSLansen reports annual results
15th Mar 20197:00 amRNSNotice of Annual Results 2018
22nd Feb 20199:32 amRNSBlock listing Interim Review - Replacement
20th Feb 20193:24 pmRNSLansen's fourth share reduction plan of Starry
1st Feb 201910:52 amRNSBlock listing Interim Review
1st Feb 201910:45 amRNSTotal Voting Rights
25th Jan 20199:59 amRNSLansen's release of its Trading Update
31st Dec 20187:00 amRNSInvestment by Lansen in Robustnique
18th Dec 20188:02 amRNSTrading Update
30th Nov 20189:34 amRNSProposed Starry Shares Disposal by Lansen
12th Oct 201810:31 amRNSChange Of Director
20th Sep 20189:43 amRNSHolding(s) in Company
31st Aug 20189:47 amRNSInterim Results
28th Aug 20182:28 pmRNSLansen reports interim results
17th Aug 20187:00 amRNSNotice of Interim Results 2018
13th Jul 20189:11 amRNSTrading Update
4th Jul 20189:05 amRNSSecond Price Monitoring Extn
4th Jul 20189:00 amRNSPrice Monitoring Extension
25th Jun 20188:00 amRNSExtension of put option in Natural Dailyhealth
6th Jun 20181:25 pmRNSLansen's partial disposal of shares in Starry
5th Jun 20189:22 amRNSResults of Annual General Meeting
2nd May 201811:20 amRNSLansen subsidiary enters distribution agreement
16th Apr 201812:43 pmRNSLansen's shareholder loan to Natural Dailyhealth
9th Apr 201811:33 amRNSAnnual Results for the Year Ended 31 December 2018
3rd Apr 201810:14 amRNSLansen's third share reduction plan of Starry
27th Mar 20189:59 amRNS2017 Lansen Annual Results
15th Mar 20187:00 amRNSNotice of Results
9th Feb 20187:43 amRNSLansen appoints Executive Director & Group CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.